Protagonist Therapeutics, Inc. (PTGX) News
Filter PTGX News Items
PTGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTGX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PTGX News From Around the Web
Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Protagonist Therapeutics Reports Granting of Inducement AwardsProtagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the ... |
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January ... |
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual MeetingProtagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the natural hormone hepcidin, has potential therapeutic ... |
Protagonist Therapeutics price target raised to $58 from $43 at JMP SecuritiesJMP Securities raised the firm’s price target on Protagonist Therapeutics (PTGX) to $58 from $43 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published first on T |
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?It is hard to get excited after looking at Protagonist Therapeutics' (NASDAQ:PTGX) recent performance, when its stock... |
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual ... |
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development CandidateOral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I initiation expected in Q425 Webcast and conference call ... |
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development CandidateWebcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company ... |
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 ReceptorProtagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD 1 and ICONIC-TOTAL 2, two pivotal Phase 3 investigational studies of icotrokinra ... |
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should KnowProtagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |